Clinical Trial Detail

NCT ID NCT03167619
Title Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (DORA)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Duke University
Indications

triple-receptor negative breast cancer

Therapies

Durvalumab + Olaparib

Olaparib

Age Groups: adult senior

No variant requirements are available.